A Strategic Enhancement to Qnovia’s Brain Trust
In a significant move to reinforce its scientific foundation, Qnovia has welcomed four distinguished experts to its Scientific Advisory Board (SAB). These appointments come at a critical juncture as Qnovia ramps up efforts to bring innovative smoking cessation therapies to the market. Neal Benowitz of the University of California at San Francisco, Ian M. Fearon, an independent consultant, Darla E. Kendzor from the University of Oklahoma Health Sciences Center, and Nicole Nollen of the University of Kansas, now lend their expertise to an already stellar board.
A Commitment to Cutting-edge Solutions
Qnovia’s CEO, Brian Quigley, emphasized the value of the new advisors, highlighting their contribution to the company’s mission of developing novel therapies for those aiming to quit smoking. “Our newly appointed advisors bring world-class scientific and multi-disciplinary expertise and reaffirm our commitment to advance novel therapies for the millions of people who seek to quit smoking,” Quigley stated. This move not only strengthens Qnovia’s scientific credibility but also underscores its commitment to making significant strides in public health.
Strategic Leadership and Regulatory Wisdom
The board’s expansion is a testament to Qnovia’s strategic foresight, complemented by the leadership of Dr. Jasjit S. Ahluwalia, a professor at Brown University and the chair and founding member of the SAB. Moreover, Mitch Zeller’s involvement as a policy and regulatory strategy advisor brings invaluable regulatory insights, given his former role as director of the FDA’s Center for Tobacco Products.
Innovation at the Forefront: The RespiRx Platform
Qnovia’s arsenal against smoking addiction is its proprietary inhaled drug delivery platform, RespiRx. The platform is poised to revolutionize the way smoking cessation therapies are administered, with the lead asset, QN-01, showing promising early results. “We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation,” Quigley remarked, setting a high bar for the product’s potential impact.
A Pivotal Year Ahead
With QN-01 demonstrating a superior pharmacokinetic profile in its initial clinical trial, Qnovia is on the brink of a major breakthrough. Plans are underway to submit the Investigational New Drug (IND) and Clinical Trial Application (CTA) to regulatory bodies, with anticipation building for the upcoming Phase 1/2 clinical study. Quigley’s optimism about 2024 being a pivotal year for Qnovia is grounded in the solid data generated thus far and the strategic bolstering of its SAB.
What’s Next for Qnovia?
As Qnovia sets its sights on FDA and MHRA approval for QN-01, the expanded Scientific Advisory Board is expected to play a critical role in navigating the complex landscape of clinical development. With such a robust team, Qnovia is not just aiming for regulatory approval but is also poised to redefine the smoking cessation market.
Your thoughts are welcome! How do you see Qnovia’s innovations impacting the future of smoking cessation? Share your views below and join the conversation on this groundbreaking journey.
